Showing results (1531-1540 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 11, 2020
Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescentNahid Golabi, Anne-Laure Larroque, Lisa Peyrard, et al.
Investigational New Drugs|April 8, 2021
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancerHyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, et al.
Investigational New Drugs|August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
Investigational New Drugs|August 11, 2020
A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasisNaminatsu Takahara, Yousuke Nakai, Hironori Ishigami, et al.
Investigational New Drugs|April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumorsAnastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Investigational New Drugs|January 22, 2015
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell linesLaura Lattanzio, Federica Tonissi, Martino Monteverde, et al.
Investigational New Drugs|April 27, 2021
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse modelYuki Fujii, Hirofumi Kamachi, Fumihiko Matsuzawa, et al.
Investigational New Drugs|April 10, 2023
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatmentsShota Omori, Koji Muramatsu, Takuya Kawata, et al.
Investigational New Drugs|April 10, 2023
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancerYingying Yang, Qingmei Zheng, Xinmei Wang, et al.
Pageof 372